Company intelligence / Profile preview

CycloLab

Budapest, Hungary

Ownership: Private
Employees: ~11
Development stage: Other

Overview

CycloLab is not developing its own therapeutics but is a global leader in cyclodextrin-based technologies for pharmaceutical formulation, drug delivery, and excipients, with over 200 cyclodextrin derivatives offered for various R&D and commercial purposes. It is cGMP-compliant and a partner to the pharmaceutical industry in early-phase drug development, formulation, and manufacturing of cyclodextrin derivatives.

Modalities: Small moleculeExcipientDrug delivery system
Industry: Chemicals & Materials

Partnerships

RotaChrom Technologies (COVID-19 remdesivir purification)

Beyond the preview

Go deeper on CycloLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CycloLab.

Explore the full profile